BIRC5 and cancer: BIRC5 expression was positively correlated with drug sensitivity for trametinib, selumetinib, RDEA119, AZ628, PD-0325901, and VX-11e (all r > 0.14, p < 0.001), and negatively associated with drug sensitivity for NSC-207895, navitoclax, vorinostat, NPK76-II-72-1, and KIN001-270 (all r < −0.10, p < 0.001) in the Genomics of Drug Sensitivity to Cancer (GDSC) database (Figure 9A and Table 3).